Study to Evaluate the Combination of Enteric-coated Mycophenolate Sodium (EC-MPS), Basiliximab, and C2-monitored Cyclosporine in de Novo Renal Transplant Recipients at Potential High Risk of Delayed Graft Function (DGF)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00154232
Recruitment Status : Completed
First Posted : September 12, 2005
Last Update Posted : November 2, 2011
Information provided by (Responsible Party):
Novartis ( Novartis Pharmaceuticals )

September 7, 2005
September 12, 2005
November 2, 2011
June 2004
March 2005   (Final data collection date for primary outcome measure)
Incidence of first episodes of BPAR at month 3 post transplant
Not Provided
Complete list of historical versions of study NCT00154232 on Archive Site
  • Incidence of patients death at month 3 post transplant.
  • Incidence of graft loss or, synonymously, graft failure)
  • The allograft will defined as lost (or: to have failed)
  • when the patient begins dialysis treatments without
  • subsequent graft recovery.
  • The time of graft failure will be defined as the time of start of dialysis, or time of nephrectomy, whatever occurs first.
  • Number of myfortic dose adjustments/discontinuations
Not Provided
Not Provided
Not Provided
Study to Evaluate the Combination of Enteric-coated Mycophenolate Sodium (EC-MPS), Basiliximab, and C2-monitored Cyclosporine in de Novo Renal Transplant Recipients at Potential High Risk of Delayed Graft Function (DGF)
A 3 Month, Multicenter, Open-label Study to Evaluate the Impact of the Immunosuppressive Combination of Enteric-Coated Mycophenolate Sodium (EC- MPS), Basiliximab and Cyclosporine for Microemulsion With C2 Monitoring, on Efficacy and Safety Outcomes in de Novo Kidney Transplant Recipients at Potential High Risk of DGF.
The aim of the study is to assess the short-term benefit of the combination of basiliximab, EC-MPS and cyclosporine microemulsion with C2 monitoring on the prophylaxis of acute rejection in a population of de novo renal transplant patients at potential high risk of DGF.
Not Provided
Phase 4
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Prevention
Renal Transplantation
Drug: Enteric-Coated Mycophenolate Sodium (EC-MPS)
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
Not Provided
Not Provided
March 2005   (Final data collection date for primary outcome measure)

Inclusion Criteria:

- Age 18-70 years old

  • Patients receiving a primary or secondary cadaveric or living donor kidney
  • Patients who have given written informed consent for study participation
  • Females capable of becoming pregnant must have a negative pregnancy test at baseline and are required to practice birth control for the duration of the study and at least for four months following the last dose of basiliximab.

Exclusion Criteria:

  • Recipient of multi-organ transplants or previously transplanted organs other than kidney
  • Recipient of dual kidney transplants
  • Recipient of a transplanted kidney from a Non-Heart Beating Donor (NHBD)
  • Recipient of a HLA identical living-donor kidney
  • Patients with a PRA level (past or current level) greater than 20%
  • Patients anticipated by investigators to require induction therapy with OKT3, ATGAM, or Thymoglobulin for any reason
  • Patients with any medical condition which, in the opinion of the investigator, would preclude the patient from participating in the study
  • Cold ischemia time larger than 36 hours.
  • Patients who have received an investigational drug or therapy within one month prior to study entry or if such therapy is to be instituted post-transplantation.
  • Female transplant candidates who are pregnant, lactating, or of childbearing potential and not willing to practice an acceptable method of contraception
  • Patients with a known hypersensitivity to cyclosporine
  • Patients with a known malignancy or a history of malignancy, other than successfully treated non-metastatic basal or squamous cell carcinoma of the skin
  • Known HIV positive antibody status
  • Evidence of any clinically relevant (per investigator determination) active infection
  • Patients unable to participate in the study for the full 3-month study period
  • Other protocol-defined exclusion criteria may apply.
Sexes Eligible for Study: All
18 Years to 70 Years   (Adult, Older Adult)
Not Provided
Contact information is only displayed when the study is recruiting subjects
Not Provided
Not Provided
Not Provided
Not Provided
Novartis ( Novartis Pharmaceuticals )
Novartis Pharmaceuticals
Not Provided
Study Director: Novartis Novartis
November 2011

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP